California State Teachers Retirement System Theseus Pharmaceuticals, Inc. Transaction History

California State Teachers Retirement System

$84.1 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.12 - $4.18 $2,406 - $4,744	-1,135 Reduced 25.41%	3,331 $13,000
Q3 2023 Nov 14, 2023	SELL	$2.66 - $10.04 $6,027 - $22,750	-2,266 Reduced 33.66%	4,466 $12,000
Q2 2023 Aug 21, 2023	BUY	$7.28 - $11.82 $3,021 - $4,905	415 Added 6.57%	6,732 $62,000
Q1 2023 May 09, 2023	SELL	$5.21 - $14.05 $2,427 - $6,547	-466 Reduced 6.87%	6,317 $56,000
Q4 2022 Feb 14, 2023	BUY	$4.69 - $8.36 $356 - $635	76 Added 1.13%	6,783 $33,000
Q3 2022 Nov 18, 2022	SELL	$5.7 - $8.68 $3,186 - $4,852	-559 Reduced 7.69%	6,707 $39,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $11,793 - $32,877	2,340 Added 47.5%	7,266 $40,000
Q1 2022 May 16, 2022	SELL	$8.75 - $14.51 $12,241 - $20,299	-1,399 Reduced 22.12%	4,926 $57,000
Q4 2021 Feb 15, 2022	BUY	$8.98 - $20.09 $56,798 - $127,069	6,325 New	6,325 $80,000

Others Institutions Holding THRX

# of Institutions

Shares Held

1.03M

Call Options Held

Put Options Held

View Full List

About Theseus Pharmaceuticals, Inc.

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

More about THRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.

Account